What stage does NGN Capital invest at?

NGN Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.

What sectors does NGN Capital focus on?

NGN Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is NGN Capital located?

NGN Capital is headquartered in New York, US.

NGN Capital

Venture capital

New York · Series A–Late Stage · 5 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

NGN Capital is a venture capital firm dedicated to the healthcare sector, backing companies across biotech, pharmaceutical, and medical device fields. The team combines deep industry, clinical, and financial experience, drawing on backgrounds in pharmaceutical development, healthcare investment banking, corporate development, and drug and device approvals. Operating from New York and Heidelberg, Germany, the firm invests through U.S. and German funds totaling roughly $450 million.

Invests inBiotech Digital Health Healthtech Medical Devices Europe Germany Israel New York North America Stamford Switzerland United States

Source: firm website, verified Aug 25, 2026.

Stage

Series A–Late Stage

New York, Connecticut, US

Instruments

Equity

Founded

2004

AUM

$450M

VC funds

Tracked investments

Team · 5 people

from the firm's website & public directories

Ken Abramowitz· Co-Founder and Managing General Partner

Kenneth S. Abramowitz co-founded NGN Capital and serves as a Managing General Partner. He previously was a Managing Director and later Senior Advisor at The Carlyle Group in New York (2001-2003), where he focused on U.S. healthcare buyouts, and spent 23 years as an analyst at Sanford C. Bernstein & Co. covering the medical-supply, hospital-management, and HMO industries, followed by a role as a healthcare fund manager at EGS Securities. He holds a B.A. from Columbia University and an M.B.A. from Harvard Business School.

k•••@ngncapital.comreveal

Kenneth J. Gorelick· Venture Partner

A physician with three decades of experience developing drugs, biologics, and medical devices. He has held senior clinical development roles at Dupont Merck and Genelabs and serves as a consultant to the biopharmaceutical industry.

William J. Gedale· Senior Advisor

Senior Advisor and co-founder of NGN Capital with an investment career dating to 1965. He founded Mount Everest Advisors, consulted for Warburg-Pincus, and led General American Investors as President and CEO.

Alexander Cuomo· Chief Financial Officer· Stamford, Connecticut, United Statesin

CFO of NGN Capital since 2008, responsible for financial reporting, tax and audit compliance, portfolio valuation, budgeting, and investor relations across the U.S. and German funds. He holds a master's in finance from Pace University.

a•••@ngncapital.comreveal

Peter Johann· Managing General Partner

Managing General Partner at NGN Capital with a background in biotech and pharmaceutical business development, having previously held senior corporate development, licensing, and marketing roles at Boehringer Ingelheim, F. Hoffmann-La Roche, and Boehringer Mannheim. He holds a Ph.D. from the Technical University Munich and serves on several life sciences company boards including Exosome Diagnostics and Vivaldi Biosciences.

p•••@ngncapital.comreveal

What they invest in

from 1 of 1 portfolio companies

Biotech ×1

HQs:United States×1

Investments · 1 tracked

founders shown can be your intro path

NeurotropeNov 2016SEC filingmedium confidence

BiotechNewark, US

Robert Weinstein(Executive Officer)Charles S. Ramat(Executive Officer, Director)

BoardLarry D. Altstiel, MD(Director)William Singer(Vice Chairman of the Board)Paul E. Freiman(Chairman of the Board)Jay M. Haft(Director)

Board seatKenneth J. Gorelick· per SEC Form D · $24.5M raise · filed Dec 2016

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Fund performance · per public LP disclosures · 2

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
NGN BioMed Opportunity IILPs: New York City Police Pension Fund	2008	—	0.6%	1.05x	1.05x
NGN BioMed Opportunity II, L.P.LPs: New York City Employees' Retirement System, Teachers' Retirement System of the City of New York, New York City Police Pension Fund +1 more	2008	—	0.6%	1.05x	1.05x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

What stage does NGN Capital invest at?: NGN Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does NGN Capital focus on?: NGN Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is NGN Capital located?: NGN Capital is headquartered in New York, US.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

OneVentures

OneVentures is a later-stage venture capital firm that backs technology and healthcare companies, providing growth equity and credit alongside strategic and operational support.

$3.3M – $13.2M

Abingworth

Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.

$15M – $30M